We’re advancing a pipeline of pioneering therapies in oncology and inflammatory diseases, enabled by our groundbreaking scientific discoveries in glyco-immunology.

Oncology

Discovery
Lead-Op
IND-Enabling
Phase 1
Phase 2
E-602 Bi-Sialidase

E-602

Bi-Sialidase

Palleon’s lead program, E-602, is a first-in-class engineered human genetic fusion from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. E-602 is designed to desialylate both immune cells and tumor cells.

E-602
Phase 1
Bifunctional PD-L1-Sialidase

Bifunctional PD-L1-Sialidase

Bifunctional PD-L1-Sialidase is a novel glyco-immunology therapeutic from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. Bifunctional PD-L1-Sialidase is designed to target PD-L1-expressing tumors and immune cells to enhance the desialylation of both tumor cells and immune cells. These molecules also block PD1/PD-L1 interaction.

Bifunctional PD-L1-Sialidase
IND-Enabling
Bifunctional HER2-Sialidase

Bifunctional HER2-Sialidase

Bifunctional HER2-Sialidase is a novel glyco-immunology therapeutic from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. Bifunctional HER2-Sialidase is designed to target HER2-expressing tumors to enhance the desialylation of tumor cells. These molecules also retain their HER2-mediated anti-tumor activity. Both HER2-low and HER2-high expressing tumors can be treated with this therapy.

In June 2022 Palleon entered into a strategic collaboration with Henlius to co-develop Bifunctional HER2-Sialidase. Under the terms of the agreement, Palleon will perform research and the parties will then share preclinical and global clinical development responsibilities and costs for the Bifunctional HER2-Sialidase. Henlius has an exclusive license to the two investigational therapies in Greater China, while Palleon retains all other global rights.

Bifunctional HER2-Sialidase
IND-Enabling

Inflammatory Diseases

Discovery
Lead-Op
IND-Enabling
Phase 1
Phase 2